Edesa Biotech, Inc.
EDSA · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.02 | -0.09 | -0.14 |
| FCF Yield | -34.37% | -52.65% | -91.01% | -15.34% |
| EV / EBITDA | -2.21 | -0.90 | -0.37 | -6.15 |
| Quality | ||||
| ROIC | -350.60% | -129.12% | -193.94% | -179.35% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.02 | 0.79 | 0.79 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 26.31% | 45.98% | 10.14% | -172.30% |
| Safety | ||||
| Net Debt / EBITDA | 0.17 | 0.64 | 0.41 | 0.59 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,556.75 | -3,475.81 | -6,552.76 | -4,239.84 |